These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 36125911)

  • 21. Verification, implementation and harmonization of automated chemiluminescent immunoassays for MPO- and PR3-ANCA detection.
    Ogrič M; Švec T; Poljšak KM; Žigon P; Hočevar A; Čučnik S
    Clin Chem Lab Med; 2024 Mar; 62(4):682-689. PubMed ID: 37870064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stratified genetic analysis reveals sex differences in MPO-ANCA-associated vasculitis.
    Ekman D; Sennblad B; Knight A; Karlsson Å; Rantapää-Dahlqvist S; Berglin E; Stegmayr B; Baslund B; Palm Ø; Haukeland H; Gunnarsson I; Bruchfeld A; Segelmark M; Ohlsson S; Mohammad AJ; Svärd A; Pullerits R; Herlitz H; Söderbergh A; Omdal R; Jonsson R; Rönnblom L; Eriksson P; Lindblad-Toh K; Dahlqvist J
    Rheumatology (Oxford); 2023 Sep; 62(9):3213-3218. PubMed ID: 37004177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
    Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
    Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence of PR3- and MPO-ANCA autoantibody specificity changes in ANCA-associated vasculitis.
    Holding S; Fisher VJ; Abuzakouk M
    Ann Clin Biochem; 2015 Mar; 52(Pt 2):297-301. PubMed ID: 24723621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The HLA region in ANCA-associated vasculitis: characterisation of genetic associations in a Scandinavian patient population.
    Lundtoft C; Knight A; Meadows JRS; Karlsson Å; Rantapää-Dahlqvist S; Berglin E; Palm Ø; Haukeland H; Gunnarsson I; Bruchfeld A; Segelmark M; Ohlsson S; Mohammad AJ; Eriksson P; Söderkvist P; Ronnblom L; Omdal R; Jonsson R; Lindblad-Toh K; Dahlqvist J
    RMD Open; 2024 Apr; 10(2):. PubMed ID: 38580345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measuring Circulating Complement Activation Products in Myeloperoxidase- and Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Wu EY; McInnis EA; Boyer-Suavet S; Mendoza CE; Aybar LT; Kennedy KB; Poulton CJ; Henderson CD; Hu Y; Hogan SL; Hu P; Xiao H; Nachman PH; Jennette JC; Falk RJ; Bunch DO
    Arthritis Rheumatol; 2019 Nov; 71(11):1894-1903. PubMed ID: 31215772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteinase-3 antineutrophil cytoplasm antibody positivity in patients without primary systemic vasculitis.
    McAdoo SP; Hall A; Levy J; Salama AD; Pusey CD
    J Clin Rheumatol; 2012 Oct; 18(7):336-40. PubMed ID: 23047533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance of MPO-ANCA and PR3-ANCA immunoassays for the stratification of specific ANCA-associated vasculitis: A systematic review and meta-analysis.
    Walker BS; Peterson LK; Koening C; White SK; Schmidt RL; Tebo AE
    Autoimmun Rev; 2022 Jun; 21(6):103100. PubMed ID: 35452854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and prognostic features of Korean patients with MPO-ANCA, PR3-ANCA and ANCA-negative vasculitis.
    Yoo J; Kim HJ; Ahn SS; Jung SM; Song JJ; Park YB; Lee SW
    Clin Exp Rheumatol; 2017; 35 Suppl 103(1):111-118. PubMed ID: 28339364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis.
    Mohammad AJ; Segelmark M
    J Rheumatol; 2014 Jul; 41(7):1366-73. PubMed ID: 24882836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative Histological Subtyping of Immune Cell Infiltrates in MPO-ANCA and PR3-ANCA Glomerulonephritis.
    Hakroush S; Tampe D; Ströbel P; Korsten P; Tampe B
    Front Immunol; 2021; 12():737708. PubMed ID: 34759920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antineutrophil cytoplasm autoantibodies from patients with systemic vasculitis activate neutrophils through distinct signaling cascades: comparison with conventional Fcgamma receptor ligation.
    Ben-Smith A; Dove SK; Martin A; Wakelam MJ; Savage CO
    Blood; 2001 Sep; 98(5):1448-55. PubMed ID: 11520794
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ANCA detection with solid phase chemiluminescence assay: diagnostic and severity association in vasculitis.
    Renuncio-García M; Calvo-Río V; Benavides-Villanueva F; Al Fazazi S; Rodríguez-Vidriales M; Escagedo-Cagigas C; Martín-Penagos L; Irure-Ventura J; López-Hoyos M; Blanco R
    Immunol Res; 2024 Feb; 72(1):128-133. PubMed ID: 37676628
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of anti-neutrophil cytoplasmic antibodies (ANCA): frequency and specificity in a sample of 191 homozygous (PiZZ) alpha1-antitrypsin-deficient subjects.
    Audrain MA; Sesboüé R; Baranger TA; Elliott J; Testa A; Martin JP; Lockwood CM; Esnault VL
    Nephrol Dial Transplant; 2001 Jan; 16(1):39-44. PubMed ID: 11208991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of different ANCA serotypes on the long-term outcome of ANCA-associated vasculitis patients.
    Qi F; Hao J; Wei W
    Ann Med; 2023; 55(2):2289614. PubMed ID: 38056010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histone modification signature at myeloperoxidase and proteinase 3 in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
    Yang J; Ge H; Poulton CJ; Hogan SL; Hu Y; Jones BE; Henderson CD; McInnis EA; Pendergraft WF; Jennette JC; Falk RJ; Ciavatta DJ
    Clin Epigenetics; 2016; 8():85. PubMed ID: 27752292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of
    Kawasaki A; Sada KE; Kusumawati PA; Hirano F; Kobayashi S; Nagasaka K; Sugihara T; Ono N; Fujimoto T; Kusaoi M; Tamura N; Kusanagi Y; Itoh K; Sumida T; Yamagata K; Hashimoto H; Makino H; Arimura Y; Harigai M; Tsuchiya N
    Front Immunol; 2023; 14():1119064. PubMed ID: 36969218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutrophil Extracellular Traps in ANCA-Associated Vasculitis.
    Söderberg D; Segelmark M
    Front Immunol; 2016; 7():256. PubMed ID: 27446086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PRTN3 variant correlates with increased autoantigen levels and relapse risk in PR3-ANCA versus MPO-ANCA disease.
    Chen DP; Aiello CP; McCoy D; Stamey T; Yang J; Hogan SL; Hu Y; Derebail VK; Wu EY; Jennette JC; Falk RJ; Ciavatta DJ
    JCI Insight; 2023 Feb; 8(4):. PubMed ID: 36626226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis.
    Ciavatta DJ; Yang J; Preston GA; Badhwar AK; Xiao H; Hewins P; Nester CM; Pendergraft WF; Magnuson TR; Jennette JC; Falk RJ
    J Clin Invest; 2010 Sep; 120(9):3209-19. PubMed ID: 20714105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.